Immunicum AB: Invitation to Investor Events
November 22 2017 - 2:00AM
YASTESTPress release
November 22, 2017
Invitation to Investor Events
Immunicum AB
(publ; First North Premier: IMMU.ST) a biopharmaceutical company
advancing a novel immune-priming cancer treatment against a variety
of solid tumors, today announced that CEO Carlos de Sousa will
present the Company as well as provide background on the previously
announced proposed Rights Issue at two upcoming investor
events.
Aktiespararna
Stora Aktiedagen in Gothenburg
Date: Monday, November 27, 2017
Presentation Time: 10:10-10:40 CET
Location: Svenska Mässan, Mässans Gata 8,
Gothenburg
Please register to attend at
https://www.aktiespararna.se/aktiviteter/stora-aktiedagen-goteborg.
Immunicum
Investor Event in Stockholm
Date: Thursday, November 30, 2017
Presentation Time: 18:00-19:00 CET
Location: United Spaces, Waterfront Building,
Floor 2, Klarabergsviadukten 63, Stockholm
After the presentation, there is an opportunity to enjoy drinks and
refreshments. Please register to attend by emailing
info@immunicum.com no later than Tuesday, November 28, 2017.
For more information, please contact:
Carlos de Sousa, CEO,
Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info@immunicum.com
Investor relations, sweden
Helena Stångberg
Hallvarsson & Halvarsson
Telephone: + 46 709 71 12 53
E-mail: ir@immunicum.com
Investor and Media Relations EU/US
Gretchen Schweitzer
Trophic Communications
Telephone: +49 172 861 8540
E-mail: ir@immunicum.com
The Company's Certified Adviser is
Redeye AB
Telephone: +46 (0) 8 545 013 31
www.redeye.se
| about IMMUNICUM AB (PUBL) Immunicum is establishing a
unique immuno-oncology approach through the development of
allogeneic, off-the-shelf cell-based therapies. Our goal is to
improve survival outcomes and quality of life by priming the
patient's own immune system to fight cancer. The company's lead
product ilixadencel, consisting of pro-inflammatory allogeneic
dendritic cells, has the potential to become a backbone component
of modern cancer combination treatments in a variety of solid tumor
indications. Founded and based in Sweden, Immunicum is publicly
traded on the Nasdaq First North Premier. www.immunicum.com |
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Immunicum AB via Globenewswire
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Apr 2023 to Apr 2024
